Transferrin-Conjugated Polymer-Coated Mesoporous Silica Nanoparticles Loaded with Gemcitabine for Killing Pancreatic Cancer Cells

2019 ◽  
Vol 3 (1) ◽  
pp. 229-240 ◽  
Author(s):  
Kusum Saini ◽  
Rajdip Bandyopadhyaya
Keyword(s):  
Pancreatic Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Conjugated Polymer ◽  
Mesoporous Silica Nanoparticles ◽  
Pancreatic Cancer Cells

scholarly journals Selective Photokilling of Human Pancreatic Cancer Cells Using Cetuximab-Targeted Mesoporous Silica Nanoparticles for Delivery of Zinc Phthalocyanine

Molecules ◽  
2018 ◽  
Vol 23 (11) ◽  
pp. 2749 ◽  
Author(s):  
Özge Er ◽  
Suleyman Colak ◽  
Kasim Ocakoglu ◽  
Mine Ince ◽  
Roger Bresolí-Obach ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Photodynamic Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Cell Line ◽  
Mesoporous Silica Nanoparticles ◽  
Human Pancreatic Cancer ◽  
Pancreatic Cancer Cells

Background: Photodynamic therapy (PDT) is a non-invasive and innovative cancer therapy based on the photodynamic effect. In this study, we sought to determine the singlet oxygen production, intracellular uptake, and in vitro photodynamic therapy potential of Cetixumab-targeted, zinc(II) 2,3,9,10,16,17,23,24-octa(tert-butylphenoxy))phthalocyaninato(2-)-N29,N30,N31,N32 (ZnPcOBP)-loaded mesoporous silica nanoparticles against pancreatic cancer cells. Results: The quantum yield (ΦΔ) value of ZnPcOBP was found to be 0.60 in toluene. In vitro cellular studies were performed to determine the dark- and phototoxicity of samples with various concentrations of ZnPcOBP by using pancreatic cells (AsPC-1, PANC-1 and MIA PaCa-2) and 20, 30, and 40 J/cm2 light fluences. No dark toxicity was observed for any sample in any cell line. ZnPcOBP alone showed a modest photodynamic activity. However, when incorporated in silica nanoparticles, it showed a relatively high phototoxic effect, which was further enhanced by Cetuximab, a monoclonal antibody that targets the Epidermal Growth Factor Receptor (EGFR). The cell-line dependent photokilling observed correlates well with EGFR expression levels in these cells. Conclusions: Imidazole-capped Cetuximab-targeted mesoporous silica nanoparticles are excellent vehicles for the selective delivery of ZnPcOBP to pancreatic cancer cells expressing the EGFR receptor. The novel nanosystem appears to be a suitable agent for photodynamic therapy of pancreatic tumors.

Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in Pancreatic Cancer Cells

2020 ◽  
Vol 20 (5) ◽  
pp. 3084-3096 ◽  
Author(s):  
Kusum Saini ◽  
R. S. Prabhuraj ◽  
Rajdip Bandyopadhyaya
Keyword(s):  
Pancreatic Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cell ◽  
Pore Diameter ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Drug Loading ◽  
Particle Diameter ◽  
Pancreatic Cancer Cells

Superior delivery of anticancer drug gemcitabine has been achieved with mesoporous silica nanoparticles (MSN), by addressing three challenges in MSN synthesis: (i) MSN was synthesized with particle diameter between 42 to 64 nm, to utilize enhanced permeability and retention effect of small particles, (ii) MSN of larger internal pore diameter (2.5–5.2 nm) was made as a tunable morphological parameter to optimize both drug loading and its release rate, in a controlled, differential manner and (iii) higher drug release at extracellular cancer-cell pH (5.5) was achieved, compared to physiological pH (7.4) of healthy cells. MSN with above features was made by the sol–gel route, with trimethylmethoxysilane as a size-quencher and hexane or decane as a pore expander. Highest gemcitabine loading of 14.92% and a cumulative release of 58% at pH 5.5 could be obtained with the optimum sample having pore diameter of 5.2 nm, in comparison to the desirably low 22% release at pH 7.4. Consequently, we obtained 60% cell growth-inhibition of pancreatic cancer cell-line (MIA Paca-2), via gemcitabine loaded MSN. This was possible because of increased gemcitabine release from MSN with larger pore diameter of 5.2 nm, simultaneously demonstrating good target-selectivity of MSN as a drug-carrier, due to engineering of its pore-size.

scholarly journals Anti-GPC1-modified mesoporous silica nanoparticles as nanocarriers for combination therapy and targeting of PANC-1 cancer cells

2021 ◽  
Author(s):  
Bianca Martins Estevão ◽  
Edson Comparetti ◽  
Nathalia Rissi ◽  
Valtencir Zucolotto
Keyword(s):  
Pancreatic Cancer ◽  
Combination Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Pancreatic Cancer Cell ◽  
Mesoporous Silica Nanoparticles ◽  
Human Pancreatic Cancer ◽  
Human Pancreatic Cancer Cell ◽  
Novel Therapeutic

We present a novel therapeutic nanoplatform based on mesoporous silica nanoparticles encapsulating Ferulic Acid/Gemcitabine and functionalized with anti-GPC1 antibodies to target human pancreatic cancer cell (PANC-1). This dynamic nanoplatform has...

scholarly journals Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro study

2017 ◽  
Vol 7 (8) ◽  
pp. 549-555 ◽  
Author(s):  
Huzaifa Hanif ◽  
Samina Nazir ◽  
Kehkashan Mazhar ◽  
Muhammad Waseem ◽  
Shazia Bano ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Targeted Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
In Vitro Study ◽  
Vitro Study

Gated Mesoporous Silica Nanoparticles for the Controlled Delivery of Drugs in Cancer Cells

Langmuir ◽  
2015 ◽  
Vol 31 (12) ◽  
pp. 3753-3762 ◽  
Author(s):  
Cristina Giménez ◽  
Cristina de la Torre ◽  
Mónica Gorbe ◽  
Elena Aznar ◽  
Félix Sancenón ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Mesoporous Silica Nanoparticles ◽  
Controlled Delivery

scholarly journals Large Pore Mesoporous Silica and Organosilica Nanoparticles for Pepstatin A Delivery in Breast Cancer Cells

Molecules ◽  
2019 ◽  
Vol 24 (2) ◽  
pp. 332 ◽  
Author(s):  
Saher Rahmani ◽  
Jelena Budimir ◽  
Mylene Sejalon ◽  
Morgane Daurat ◽  
Dina Aggad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Cathepsin D ◽  
Breast Cancer Cells ◽  
Potent Inhibitor ◽  
Mesoporous Silica Nanoparticles ◽  
Sol Gel ◽  
Pepstatin A

(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides.

Mesoporous silica nanoparticles functionalized with a dialkoxide diorganotin(IV) compound: In search of more selective systems against cancer cells

2020 ◽  
Vol 300 ◽  
pp. 110154 ◽  
Author(s):  
Diana Díaz-García ◽  
Lucia Sommerova ◽  
Andrea Martisova ◽  
Hana Skoupilova ◽  
Sanjiv Prashar ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Mesoporous Silica Nanoparticles
Sign in / Sign up

Export Citation Format

Share Document